

A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine japanese patients with TSC of different disease severity.

15) *Arch Dermatol* in press

A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex

16) *British Journal of Dermatology* 165: 1365-2133, 2011

Treatment of Facial Angiofibromas with Topical Application of Oral Rapamycin Solution (1 mg/mL) in Two Patients with Tuberous Sclerosis

同意文書

私は、「薬事申請を目指した結節性硬化症に伴う顔面血管線維腫に対する安全性の高い外用剤の開発のための臨床試験」に参加するに当たり、以下の内容について説明を受け、十分に理解した上で、自らの自由意思により本治験に参加することに同意します。

(説明事項)

- | | |
|----------------------------------|---------------------|
| 1. 治験とは？ | 8. 治験に関する新たな情報について |
| 2. あなたの病気（結節性硬化症）について | 9. 健康被害が発生した場合について |
| 3. 治験の目的 | 10. 治験への参加とその撤回について |
| 4. 治験の方法 | 11. 治験を中止する場合について |
| 5. この治験に参加いただく前に確認したいこと | 12. プライバシーの保護について |
| 6. 予測される患者さんの利益と生じるおそれのある不利益について | 13. 治験の費用について |
| 7. 結節性硬化症に対する治療法について | 14. 守っていただきたいこと |
| | 15. 担当医師への連絡 |

患者さん署名欄

患者さん氏名： _____

同意日：平成 年 月 日

また、生検検査についても説明を受け、十分理解した上で、自らの自由意思により生検検査に同意します。

患者さん氏名： _____

同意日：平成 年 月 日

代諾者署名欄

代諾者氏名： _____ (患者さんとの続柄： _____)

同意日：平成 年 月 日

患者さん本人が署名できない理由： _____

(生検検査への同意)

代諾者氏名： _____ (患者さんとの続柄： _____)

同意日：平成 年 月 日

患者さん本人が署名できない理由： _____

担当医師署名欄

担当医師氏名： _____

説明日：平成 年 月 日

説明補助者署名欄

治験協力者氏名： _____

説明日：平成 年 月 日

II. 研究成果の刊行に関する一覧表

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S, Katayama I	A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex.	Arch Dermatol	148(1)	138-9	2012
Kotobuki Y, Tanemura A, Yang L, Itoi S, Wataya-Kaneda M, Murota H, Fujimoto M, Serada S, Naka T, Katayama I	Dysregulation of Melanocyte Function by Th17-related Cytokines: Significance of Th17 Cell Infiltration in Autoimmune Vitiligo Vulgaris.	Pigment Cell & Melanoma Research	25(2)	219-30	2012
Hanafusa T, Tamai K, Umegaki N, Yamaguchi Y, Fukuda S, Nishikawa Y, Yaegashi N, Okuyama R, McGrath JA, Katayama I	The course of pregnancy and childbirth in three mothers with recessive dystrophic epidermolysis bullosa.	Clin Exp Dermatol.	37(1)	10-4	2012
Arase A, Wataya-Kaneda M, Oiso N, Tanemura A, Kawada A, Suzuki T, Katayama I	Repigmentation of leukoderma in a piebald patient associated with a novel c-KIT gene mutation, G592E, of the tyrosine kinase domain.	J Dermatol Sci	58	147-9	2011
Kono M, Akiyama M, Kondo T, Suzuki T, Suganuma M, Wataya-Kaneda M, Lam J, Shibaki A, Tomita Y	Four novel ADAR1 gene mutations in patients with dyschromatosis symmetrica hereditaria.	J Dermatol	38	1-3	2011
Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S, Katayama I	A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.	Br J Dermatol.	165(4)	912-6	2011
Murakami Y, Wataya-Kaneda M, Terao M, Azukizawa H, Murota H, Nakata Y, Katayama I	Peculiar distribution of tumorous xanthomas in an adult case of erdheim-chester disease complicated by atopic dermatitis.	Case Rep Dermatol	3(2)	107-12	2011
Tamai K, Yamazaki T, Chino T	PDGFR α -positive cells in bone marrow are mobilized by HMGB1 to regenerate injured epithelia.	Proc Natl Acad Sci USA	108(16)	6609-14.	2011
Koga H, Hamada T, Ishii N, Fukuda S, Sakaguchi S, Nakano H, Tamai K, Sawamura D, Hashimoto T	Exon 87 skipping of the COL7A1 gene in dominant Dystrophic epidermolysis bullosa	J Dermatol.	38(5)	89-92	2011
Fujita H, Tamai K, Kawachi M, Saga K, Shimbo T, Yamazaki T, Kaneda Y	Methyl-beta cyclodextrin alters the production and infectivity of Sendai virus.	Arch Virol.	56(6)	995-1005	2011
Umegaki N, Nakano H, Tamai K, Mitsunashi Y, Akasaka E, Sawamura D, Katayama I	Vörner type palmoplantar keratoderma: novel KRT9 mutation associated with knuckle pad-like lesion and recurrent mutation causing digital mutilation.	Br J Dermatol.	65(1)	199-201	2011
Nakagami H, Nishikawa T, Tamura N, Maeda A, Hibino H, Mochizuki M, Shimosato T, Moriya T, Morishita R, Tamai K, Tomono K, Kaneda Y.	Modification of a novel angiogenic peptide, AG30, for the development of novel therapeutic agents.	J Cell Mol Med.		[Epub ahead of print]	
Kiyohara E, Tamai K, Katayama I, Kaneda Y	The combination of chemotherapy with HVJ-E Containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma.	Gene Ther.		[Epub ahead of print]	
Morimoto S, Oka Y, Tsuboi A, Tanaka Y, Fujiki F, Nakajima H, Hosen N, Nishida S, Nakata J, Nakae Y, Maruno M, Myoui A, Enomoto T, Izumoto S, Sekimoto M, Kagawa N, Hashimoto N, Yoshimine T, Oji Y, Kumanogoh A, Sugiyama H	Biased usage of T cell receptor β -chain variable region genes of WT1 (Wilms' tumor gene)-specific CD8(+) T cells in patients with solid tumors and healthy donors.	Cancer Sci.	103(3)	408-14	2012

Ren LM, Arahira T, Todo M, Yoshikawa H, <u>Myoui A</u>	Biomechanical evaluation of porous bioactive ceramics after implantation: micro CT-based three-dimensional finite element analysis.	J Mater Sci Mater Med.	23(2)	463-72	2012
Tomonaga M, Hashimoto N, Tokunaga F, Onishi M, <u>Myoui A</u> :Yoshikawa H, Iwai K.	Activation of nuclear factor-kappa B by linear ubiquitin chain assembly complex contributes to lung metastasis of osteosarcoma cells.	Int J Oncol.	40(2):	409-17	2012
Kawato Y, Hirao M, Ebina K, Tamai N, Shi K, Hashimoto J, Yoshikawa H, <u>Myoui A</u>	Nkx3.2-induced suppression of Runx2 is a crucial mediator of hypoxia-dependent maintenance of chondrocyte phenotypes.	Biochem Biophys Res Commun.	416(1-2)	205-10	2011
Tao H, Okamoto M, Nishikawa M, Yoshikawa H, <u>Myoui A</u>	P38 Mitogen-Activated Protein Kinase Inhibitor, FR167653, Inhibits Parathyroid Hormone Related Protein-Induced Osteoclastogenesis and Bone Resorption.	PLoS ONE	6(8)	6(8)	2011
Yokoi M, Hattori K, Narikawa K, Ohgushi H, Tadokoro M, Hoshi K, Takato T, <u>Myoui A</u> , Nanno K, Kato Y, Kanawa M, Sugawara K, Kobo T, Ushida T	Feasibility and limitations of the round robin test for assessment of in vitro chondrogenesis evaluation protocol in a tissue-engineered medical product.	J Tissue Eng Regen Med.		2011 Aug 2. doi: 10.1002/term.460. [Epub ahead of print]	
Takenaka S, Hashimoto N, Araki N, Hamada K, Naka N, Joyama S, Kakunaga S, Ueda T, <u>Myoui A</u> , Yoshikawa H.	Eleven Cases of Cardiac Metastases from Soft-tissue S	Jpn J Clin Oncol.	41(4)	514-8	2011
Sugiyasu K, Nanno K, Tamai N, Hashimoto N, Kishida Y, Yoshikawa H, <u>Myoui A</u>	Radio-sensitization of the murine osteosarcoma cell line LM8 with parthenolide, a natural inhibitor of NF- κ B.	Oncol Lett	2:	407-12	2011
Kawachi Y, Taguchi S, Fujisawa Y, Furuta J, Nakamura Y, Ishii Y, <u>Otsuka F</u>	Linear childhood discoid lupus erythematosus following the lines of Blaschko: successfully treated with topical tacrolimus.	Pediatr Dermatol.	28(2)	205-7	2011
Kawachi Y, Tanaka R, Fujisawa Y, Furuta J, Nakamura Y, Ishii Y, <u>Otsuka F</u>	Superficial malignant peripheral nerve sheath tumor arising from a solitary cutaneous neurofibroma in a non-NF1 patient.	Eur J Dermatol.	21(1):	125-6	2011
Fujisawa Y, Ito M, Mori K, Okada S, Nakamura Y, Kawachi Y, <u>Otsuka F</u>	Intra-arterial mitoxantrone/paclitaxel in angiosarcoma of the lower limb associated with chronic lymphedema (Stewart-Treves syndrome) in a patient with cervical cancer.	Eur J Dermatol.	21(1)	119-20	2011
Fujisawa Y, Sugita S, Kawachi Y, <u>Otsuka F</u>	Extra-abdominal desmoid tumor in the subcutis of the thigh.	J Dermatol.	38(8):	810-2	2011
Fujisawa Y, Nakamura Y, Kawachi Y, <u>Otsuka F</u>	A custom-made, low-cost intraoperative fluorescence navigation system with indocyanine green for sentinel lymph node biopsy in skin cancer.	Dermatology	222(3):	261-8	2011
Fujisawa Y, Nabekura T, Kawachi Y, <u>Otsuka F</u>	Onodera M. Enforced ROR(γ)t expression in haematopoietic stem cells increases regulatory T cell number, which reduces immunoreactivity and attenuates hypersensitivity in vivo.	Asian Pac J Allergy Immunol.	29(1)	86-93	2011
Hirota A, Kawachi Y, Yamamoto M, Koga T, Hamada K, <u>Otsuka F</u>	Acceleration of UVB-induced photoageing in nrf2 gene-deficient mice.	Exp Dermatol	20(8)	664-8	2011
Nakamura Y, Fujisawa Y, Maruyama H, Furuta J, Kawachi Y, <u>Otsuka F</u>	Intraoperative mapping with isosulfan blue of lymphatic leakage during inguinal lymph node dissection (ILND) for skin cancer for the prevention of postoperative lymphocele.	J Surg Oncol.	104(6)	657-60	2011

著者氏名	論文タイトル名	編集者	書籍名	出版社名	出版地	出版年	ページ
Kawachi Y, Otsuka F	Treatment of keratinization disorders.		The color atlas of disorders of keratinizatio.(sec ond edition),	Kyowa Kikaku, LTD.	Tokyo	2011	49-52

